Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Nov;83(9):1216–1222. doi: 10.1054/bjoc.2000.1424

Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo

M Guba 1, A-K Bosserhoff 2,3, M Steinbauer 1, C Abels 3, M Anthuber 1, R Buettner 2, K-W Jauch 1
PMCID: PMC2363599  PMID: 11027436

Abstract

The secreted MIA protein is strongly expressed by advanced primary and metastatic melanomas but not in normal melanocytes. Previous studies have shown that MIA serum levels correlate with clinical tumour progression in melanoma patients. To provide direct evidence that MIA plays a role in metastasis of malignant melanomas, A-mel 3 hamster melanoma cells were transfected with sense- and antisense rhMIA cDNA and analysed subsequently for changes in their tumorigenic and metastatic potential. Enforced expression of MIA in A-mel 3 cells significantly increased their metastatic potential without affecting primary tumour growth, cell proliferation or apoptosis rate in hamsters, compared with control or antisense transfected cells. Additionally, MIA overexpressing transfectants showed a higher rate of both tumour cell invasion and extravasation. Cells transfected with MIA antisense generally exerted an opposite response. The above changes in function attributed to the expression of MIA may underlie the contribution of MIA to the malignant phenotype. © 2000 Cancer Research Campaign

Keywords: MIA, intravital microscopy, tumour cell invasion, melanoma

Full Text

The Full Text of this article is available as a PDF (269.1 KB).

Footnotes

Both authors have contributed equally to this work

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apfel R., Lottspeich F., Hoppe J., Behl C., Dürr G., Bogdahn U. Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res. 1992 Dec;2(5-6):327–336. doi: 10.1097/00008390-199212000-00006. [DOI] [PubMed] [Google Scholar]
  2. Blesch A., Bosserhoff A. K., Apfel R., Behl C., Hessdoerfer B., Schmitt A., Jachimczak P., Lottspeich F., Buettner R., Bogdahn U. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 1994 Nov 1;54(21):5695–5701. [PubMed] [Google Scholar]
  3. Bogdahn U., Apfel R., Hahn M., Gerlach M., Behl C., Hoppe J., Martin R. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res. 1989 Oct 1;49(19):5358–5363. [PubMed] [Google Scholar]
  4. Bosserhoff A. K., Golob M., Buettner R., Landthaler M., Hein R. MIA ("melanoma inhibitory activity"). Biologische Funktionen und klinische Relevanz beim malignen Melanom. Hautarzt. 1998 Oct;49(10):762–769. doi: 10.1007/s001050050822. [DOI] [PubMed] [Google Scholar]
  5. Bosserhoff A. K., Kaufmann M., Kaluza B., Bartke I., Zirngibl H., Hein R., Stolz W., Buettner R. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997 Aug 1;57(15):3149–3153. [PubMed] [Google Scholar]
  6. Bosserhoff A. K., Kondo S., Moser M., Dietz U. H., Copeland N. G., Gilbert D. J., Jenkins N. A., Buettner R., Sandell L. J. Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn. 1997 Apr;208(4):516–525. doi: 10.1002/(SICI)1097-0177(199704)208:4<516::AID-AJA7>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  7. Buettner R., Yim S. O., Hong Y. S., Boncinelli E., Tainsky M. A. Alteration of homeobox gene expression by N-ras transformation of PA-1 human teratocarcinoma cells. Mol Cell Biol. 1991 Jul;11(7):3573–3583. doi: 10.1128/mcb.11.7.3573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dellian M., Richert C., Gamarra F., Goetz A. E. Photodynamic eradication of amelanotic melanoma of the hamster with fast acting photosensitizers. Int J Cancer. 1996 Jan 17;65(2):246–248. doi: 10.1002/(SICI)1097-0215(19960117)65:2<246::AID-IJC19>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  9. Fidler I. J. Critical determinants of melanoma metastasis. J Investig Dermatol Symp Proc. 1996 Apr;1(2):203–208. [PubMed] [Google Scholar]
  10. Fidler I. J. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990 Oct 1;50(19):6130–6138. [PubMed] [Google Scholar]
  11. Hangan D., Morris V. L., Boeters L., von Ballestrem C., Uniyal S., Chan B. M. An epitope on VLA-6 (alpha6beta1) integrin involved in migration but not adhesion is required for extravasation of murine melanoma B16F1 cells in liver. Cancer Res. 1997 Sep 1;57(17):3812–3817. [PubMed] [Google Scholar]
  12. Jacob K., Bosserhoff A. K., Wach F., Knüchel R., Klein E. C., Hein R., Buettner R. Characterization of selected strongly and weakly invasive sublines of a primary human melanoma cell line and isolation of subtractive cDNA clones. Int J Cancer. 1995 Mar 3;60(5):668–675. doi: 10.1002/ijc.2910600517. [DOI] [PubMed] [Google Scholar]
  13. Killion J. J., Radinsky R., Fidler I. J. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998;17(3):279–284. doi: 10.1023/a:1006140513233. [DOI] [PubMed] [Google Scholar]
  14. Koehler M. R., Bosserhoff A., von Beust G., Bauer A., Blesch A., Buettner R., Schlegel J., Bogdahn U., Schmid M. Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics. 1996 Jul 1;35(1):265–267. doi: 10.1006/geno.1996.0352. [DOI] [PubMed] [Google Scholar]
  15. Koop S., MacDonald I. C., Luzzi K., Schmidt E. E., Morris V. L., Grattan M., Khokha R., Chambers A. F., Groom A. C. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res. 1995 Jun 15;55(12):2520–2523. [PubMed] [Google Scholar]
  16. Kopf A. W., Salopek T. G., Slade J., Marghoob A. A., Bart R. S. Techniques of cutaneous examination for the detection of skin cancer. Cancer. 1995 Jan 15;75(2 Suppl):684–690. doi: 10.1002/1097-0142(19950115)75:2+<684::aid-cncr2820751411>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  17. Ledda M. F., Adris S., Bravo A. I., Kairiyama C., Bover L., Chernajovsky Y., Mordoh J., Podhajcer O. L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med. 1997 Feb;3(2):171–176. doi: 10.1038/nm0297-171. [DOI] [PubMed] [Google Scholar]
  18. Morris V. L., MacDonald I. C., Koop S., Schmidt E. E., Chambers A. F., Groom A. C. Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: videomicroscopic analysis. Clin Exp Metastasis. 1993 Sep;11(5):377–390. doi: 10.1007/BF00132981. [DOI] [PubMed] [Google Scholar]
  19. Sage E. H., Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem. 1991 Aug 15;266(23):14831–14834. [PubMed] [Google Scholar]
  20. Schreiner C., Fisher M., Hussein S., Juliano R. L. Increased tumorigenicity of fibronectin receptor deficient Chinese hamster ovary cell variants. Cancer Res. 1991 Mar 15;51(6):1738–1740. [PubMed] [Google Scholar]
  21. Stallmach A., von Lampe B., Matthes H., Bornhöft G., Riecken E. O. Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. Gut. 1992 Mar;33(3):342–346. doi: 10.1136/gut.33.3.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stetler-Stevenson W. G., Aznavoorian S., Liotta L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541–573. doi: 10.1146/annurev.cb.09.110193.002545. [DOI] [PubMed] [Google Scholar]
  23. Weilbach F. X., Bogdahn U., Poot M., Apfel R., Behl C., Drenkard D., Martin R., Hoehn H. Melanoma-inhibiting activity inhibits cell proliferation by prolongation of the S-phase and arrest of cells in the G2 compartment. Cancer Res. 1990 Nov 1;50(21):6981–6986. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES